Skip to main content

Table 1 Clinical characteristics of the study cohort

From: Thyroid disease and cancer in kidney transplantation: a single-center analysis

  With nodule (n=204) Without nodule (n=556) P
Male (%) 48% 47% Ns
Living/Deceased 40/164 60/494 Ns
Age (years) 48 ±12.3 54 ±10.5 < 0.04
Cause of ESRD (n,%)
 Glomerulonephritis 95 (46.6) 265 (47.6) Ns
 Polycystic Kidney Disease 40 (19.7) 87 (15.7) Ns
 Diabetes 30 (14.7) 60 (10.8) Ns
 Other causes 39 (19.1) 144 (25.9) Ns
Waiting list (months) 21 ±10.4 18.2 ±16.4 Ns
Pretransplant dialysis 32 ±16.3 29 ±22.3 < 0.05
Donor age 55.6 ± 15.1 54.2 ±18.1 Ns
Immunosuppression (n, %)
 Induction 60 (29.4) 160 (28.2) Ns
 TAC+MPA+Ster 170 (83.3) 470 (83) Ns
 CYA+MPA+Ster 20 (9.8) 60 (10.6) Ns
 Eve+MPA+Ster 24 (11.7) 36 (6.3) Ns
BMI (KG/m2) 25 ±4.7 26.1 ±3.9 Ns
Serum Creatinine (mg/dL) 1.53 ±0.7 1.49 ±0.6 Ns
  1. ESRD end-stage renal disease, TAC tacrolimus, MPA mycophenolic acid, Ster steroids, CyA cyclosporine, EVE, everolimus, BMI body mass index NS, not significant